CA2060176A1 - Compositions pharmaceutiques a petites particules - Google Patents

Compositions pharmaceutiques a petites particules

Info

Publication number
CA2060176A1
CA2060176A1 CA2060176A CA2060176A CA2060176A1 CA 2060176 A1 CA2060176 A1 CA 2060176A1 CA 2060176 A CA2060176 A CA 2060176A CA 2060176 A CA2060176 A CA 2060176A CA 2060176 A1 CA2060176 A1 CA 2060176A1
Authority
CA
Canada
Prior art keywords
microspheres
small particle
drug compositions
microsphere
particle drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2060176A
Other languages
English (en)
Other versions
CA2060176C (fr
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10665744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2060176(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2060176A1 publication Critical patent/CA2060176A1/fr
Application granted granted Critical
Publication of CA2060176C publication Critical patent/CA2060176C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002060176A 1989-11-04 1990-11-01 Compositions pharmaceutiques a petites particules Expired - Fee Related CA2060176C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8924935A GB2237510B (en) 1989-11-04 1989-11-04 Small particle drug compositions for nasal administration
GB8924935.3 1989-11-04
PCT/GB1990/001676 WO1991006282A1 (fr) 1989-11-04 1990-11-01 Compositions pharmacologiques a particules de taille reduite

Publications (2)

Publication Number Publication Date
CA2060176A1 true CA2060176A1 (fr) 1991-05-05
CA2060176C CA2060176C (fr) 2001-01-09

Family

ID=10665744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002060176A Expired - Fee Related CA2060176C (fr) 1989-11-04 1990-11-01 Compositions pharmaceutiques a petites particules

Country Status (10)

Country Link
EP (1) EP0500594B1 (fr)
JP (1) JP2974409B2 (fr)
AT (1) ATE162072T1 (fr)
CA (1) CA2060176C (fr)
DE (1) DE69031950T2 (fr)
DK (1) DK0500594T3 (fr)
ES (1) ES2112253T3 (fr)
GB (1) GB2237510B (fr)
GR (1) GR3026367T3 (fr)
WO (1) WO1991006282A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
EP0621775B1 (fr) * 1992-01-17 1997-08-06 ALFATEC-PHARMA GmbH Comprimes contenant des medicaments peptidiques, leur fabrication et leur application
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
ES2068762B1 (es) * 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
WO1995034582A1 (fr) * 1994-06-16 1995-12-21 Pharmacia S.P.A. Amidons bioadhesifs et leur procede de preparation
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
CA2213638C (fr) 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols contenant des dispersions de nanoparticules
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6344202B1 (en) 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
KR100796220B1 (ko) * 1998-06-29 2008-01-21 넥타르 테라퓨틱스 미립자 전달 시스템 및 사용 방법
WO2000012063A1 (fr) 1998-08-26 2000-03-09 Teijin Limited Compositions en poudre s'administrant par voie nasale
EP1143896B1 (fr) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methodes pour hydrater des muqueuses nasales
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
US6811783B1 (en) 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2002060486A2 (fr) * 2001-01-29 2002-08-08 Fresco Bernard B Procede et dispositif permettant l'administration de medicaments a un organisme
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
WO2008040488A1 (fr) 2006-10-04 2008-04-10 M & P Patent Aktiengesellschaft Système d'administration à libération contrôlée pour application nasale de neurotransmetteurs
ES2649112T3 (es) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN107582526A (zh) * 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015111062A1 (fr) 2014-01-27 2015-07-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoencapsulation de composés hydrophiles actifs
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520247A (en) * 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1520248A (en) * 1975-07-24 1978-08-02 Fisons Ltd Sodium cromoglycate containing medicament
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
EP0187433B1 (fr) * 1983-08-01 1990-12-27 Teijin Limited Composition pharmaceutique poudreuse pour l'application sur la muqueuse de la cavité orale ou nasale
DE3341001A1 (de) * 1983-11-12 1985-05-23 Krause, Hans Jürgen Nanopartikel aus bioabbaubarem, synthetischem material, verfahren zu deren herstellung und ihre anwendung
EP0248051A1 (fr) * 1985-11-29 1987-12-09 FISONS plc Composition pharmaceutique comprenant du cromoglycate de sodium
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system

Also Published As

Publication number Publication date
GB2237510A (en) 1991-05-08
GB8924935D0 (en) 1989-12-28
ES2112253T3 (es) 1998-04-01
JPH05501408A (ja) 1993-03-18
WO1991006282A1 (fr) 1991-05-16
GB2237510B (en) 1993-09-15
ATE162072T1 (de) 1998-01-15
JP2974409B2 (ja) 1999-11-10
GR3026367T3 (en) 1998-06-30
DK0500594T3 (da) 1998-09-14
DE69031950D1 (de) 1998-02-19
EP0500594B1 (fr) 1998-01-14
DE69031950T2 (de) 1998-05-28
CA2060176C (fr) 2001-01-09
EP0500594A1 (fr) 1992-09-02

Similar Documents

Publication Publication Date Title
CA2060176A1 (fr) Compositions pharmaceutiques a petites particules
EP0943326B2 (fr) Composition pulverulente destinee a une administration nasale
US6103269A (en) Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
EP0918535B1 (fr) Composition a liberation continue sous forme de medicaments encapsules dans des microparticules d'acide hyaluronique
CA2012791A1 (fr) Base de gel en aerosol et preparation de gel en aerosol
CA2045472A1 (fr) Compositions pour l'administration de medicaments
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
CA2150464A1 (fr) Composition pharmaceutique pour administration intraduodenale
CA2058428A1 (fr) Formulations analgesiques
EP1025840A3 (fr) Compositions et procedes d'administration de medicaments par voie orale
CA2166891A1 (fr) Methode pour l'obtention de formes posologiques par lyophylisation
CA2072933A1 (fr) Comprime mecaniquement stable, pouvant se dissoudre aisement, et compose de petites particules renfermant des ingredients actifs
KR910004180A (ko) 저작성 약제학적 정제를 제조하기 위한 회전과립화 공정 및 맛을 은폐하기 위한 피복공정
CA2090561A1 (fr) Systeme permettant l'administration pulsatile d'une dose de minocycline par jour
CA2131285A1 (fr) Compositions pharmaceutiques pour inhalation
CA2093666A1 (fr) Preparation pharmaceutique sans solvant pour administration par voie orale permettant une liberation prolongee de l'ingredient actif et methode de fabrication de ladite preparation
CA2192086A1 (fr) Pilules
IE893161L (en) Psyllium-containing products
CA2020877A1 (fr) Creme de tretinoine emulsifiee stable
EP0935460B1 (fr) Compositions pharmaceutiques a gout masque
UA40636C2 (uk) Фармацевтична композиція для одержання стабільного порошку, яка містить як активний компонент асоціацію ацетилсаліцилової кислоти та метоклопраміду, фармацевтичний препарат у формі порошку та спосіб одержання цього препарату
CA2139790A1 (fr) Comprimes d'acide thioctique de granulometrie donnee
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
IE902292L (en) Sustained release pharmaceuticals

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed